AAVs are becoming the leading viral vector in the development of gene-based advanced therapy medicinal products (ATMPs). Their success is due to their intrinsic properties: they are primarily non-integrating as they persist within cells as episomes, and have a broad tropism with eleven serotypes that have the ability to infect specific cell types. A major challenge today is manufacturing sufficient quantities of AAV in order to treat larger groups of patients. FectoVIR®-AAV is a novel class of animal free transfection reagent specifically developed for industrial scale production of recombinant AAV (rAAV) viral vectors in suspension HEK-293 cell types. FectoVIR®-AAV transfection reagent guarantees higher rAAV viral titers, improved flexibility and scalability for industrial scale manufacturing.
A Frequently Asked Question section about FectoVIR®-AAV can be found here.